<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013086</url>
  </required_header>
  <id_info>
    <org_study_id>PekingUMCH AB-3PRGD2</org_study_id>
    <nct_id>NCT05013086</nct_id>
  </id_info>
  <brief_title>177Lu-AB-3PRGD2 in Patients With Non Small Cell Lung Cancer</brief_title>
  <official_title>Therapeutic Efficiency and Response to 177Lu-AB-3PRGD2 in Patients With Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-controlled, non-randomized study to assess the safety and measure&#xD;
      image-based absorbed dose of 177Lu-AB-3PRGD2 in patients with Non Small Cell Lung Cancerr&#xD;
      (NSCLC) who will undergo radioliagnd therapy using 177Lu-AB-3PRGD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Integrin αvβ3 is highly expressed in some tumor cells and neovascularization, which is an&#xD;
      ideal target for diagnosis and treatment of NSCLC. 177Lu-AB-3PRGD2, is a kind of new drug&#xD;
      based on independent research and development in China, provide an effective target for the&#xD;
      treatment of NSCLC. All patients underwent whole-body 68Ga-RGD PET/CT for selection and&#xD;
      accepted intravenous injection with single dose 1.11 GBq (30 mCi) of 177Lu-AB-3PRGD2 within&#xD;
      one week. 1-2 ml venous blood was collected at 30min, 60min, 120min, 1d, 3d, 5d and 7d after&#xD;
      administration to detect radioactivity count, respectively. Then monitored at 2, 24, 72, 120&#xD;
      and 168 h after 177Lu-AB-3PRGD2 administration with serial whole body planar and SPECT/CT&#xD;
      imaging. Analyze and calculate the internal radiation dose of 177Lu-AB-3PRGD2 and evaluate&#xD;
      its therapeutic efficiency and response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>StandarStandardized uptake value of 177Lu-AB-3PRGD2 in normal organs and NSCLC.</measure>
    <time_frame>1 year</time_frame>
    <description>The semiquantitative analysis will be performed by the same person for all the cases, and the standardized uptake value at each time point in normal organs and NSCLC will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events collection</measure>
    <time_frame>2 months</time_frame>
    <description>Adverse events within 2 months after the injection and scanning of patients will be followed and assessed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1.11 GBq of 177Lu-AB-3PRGD2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients were intravenously injected with the dose about 1.11GBq (30 mCi) of 177Lu-AB-3PRGD2 and underwent 68Ga-RGD PET/CT scans before and after the treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.11 GBq of 177Lu-AB-3PRGD2</intervention_name>
    <description>accepted intravenous injection of 177Lu-AB-3PRGD2</description>
    <arm_group_label>1.11 GBq of 177Lu-AB-3PRGD2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  confirmed NSCLC patients;&#xD;
&#xD;
          -  tumor lesions with high RGD untake confirmed on 68Ga-RGD PET/CT within one week before&#xD;
             the injection of 177Lu-AB-3PRGD2;&#xD;
&#xD;
          -  signed written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  the exclusion criteria were a serum creatinine level of more than 150 μmol per liter,&#xD;
             a hemoglobin level of less than 10.0 g/dl, a white-cell count of less than 4.0× 109/L,&#xD;
             a platelet count of less than 100 × 109/L, a total bilirubin level of more than 3&#xD;
             times the upper limit of the normal range and a serum albumin level of more than 3.0 g&#xD;
             per deciliter, cardiac insufficiency including carcinoid heart valve disease, a severe&#xD;
             allergy or hypersensitivity to radiographic contrast material, claustrophobia;&#xD;
&#xD;
          -  any medical condition that in the opinion of the investigator may significantly&#xD;
             interfere with study compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaohui Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhaohui Zhu, MD</last_name>
    <phone>86-13611093752</phone>
    <email>13611093752@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guochang Wang, MD</last_name>
    <phone>86-18516822732</phone>
    <email>guochang1007@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaohui Zhu, MD</last_name>
      <phone>86-13611093752</phone>
      <email>13611093752@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Guochang Wang, MD</last_name>
      <phone>86-18516822732</phone>
      <email>guochang1007@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

